Schrödinger, Inc. has embarked on an initiative to enhance its computational platform for early predicting toxicology risk in drug discovery. The initiative aims to create a computational solution that optimizes drug development candidates and minimizes the risk of development failure due to off-target binding.
This expansion of Schrödinger’s “predict first” digital laboratory leverages its physics-based platform and NVIDIA’s AI technologies. Broad implementation of predictive toxicology promises to accelerate progress from target identification to drug candidates and mitigate toxicity risks in preclinical and clinical trials.
Safety concerns often delay or hinder drug development, prompting the U.S. Food and Drug Administration’s focus on the Predictive Toxicology Roadmap. The Bill & Melinda Gates Foundation has granted $10 million to support the scientific research underlying this initiative in its initial year.
Once developed, the technology will be accessible to Gates Foundation grantees worldwide, facilitating accelerated drug development for diseases prevalent in low- and middle-income countries. These tools will also be available to Schrödinger’s customers and used in its proprietary drug discovery programs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
